Estrogen therapy used in combination with selective serotonin reuptake inhibitor (SSRI) treatment improves SSRI efficacy for the treatment of mood disorders. Desensitization of serotonin 1A (5-HT 1A ) receptors, which takes one to two weeks to develop in animals, is necessary for SSRI therapeutic efficacy. Estradiol modifies 5-HT 1A receptor signaling and induces a partial desensitization in the paraventricular nucleus (PVN) of the rat within two days, but the mechanisms underlying this effect are currently unknown. The purpose of this study was to identify the estrogen receptor necessary for estradiol-induced 5-HT 1A receptor desensitization. We previously showed that estrogen receptor β is not necessary for 5-HT 1A receptor desensitization and that selective activation of estrogen receptor GPR30 mimics the effects of estradiol in rat PVN. Here, we used a recombinant adenovirus containing GPR30 siRNAs to decrease GPR30 expression in the PVN. Reduction of GPR30 prevented estradiol-induced desensitization of 5-HT 1A receptor as measured by hormonal responses to the selective 5-HT 1A receptor agonist, (+)8-OH-DPAT. To determine the possible mechanisms underlying these effects, we investigated protein and mRNA levels of 5-HT 1A receptor signaling components including 5-HT 1A receptor, Gαz, and RGSz1. We found that two days of estradiol increased protein and mRNA expression of RGSz1, and decreased 5-HT 1A receptor protein but increased 5-HT 1A mRNA; GPR30 knockdown prevented the estradiol-induced changes in 5-HT 1A receptor protein in the PVN. Taken together, these data demonstrate that GPR30 is necessary for estradiol-induced changes in the 5-HT 1A receptor signaling pathway and desensitization of 5-HT 1A receptor signaling.
Introduction
Women in peri-to post-menopausal states experience a fluctuation, then decline, in estrogen levels (Banger, 2002) . The greatest reduction of estrogen levels is observed during the late menopausal transition and the first year post-menopause (Archer et al., 1999; Santoro et al., 1996; Schmidt et al., 2004) . Decreased levels of estrogens are associated with various neuropsychiatric disorders such as depression, anxiety, and panic disorders in women (Arpels, 1996) . During peri-menopause, there is a higher incidence of first onset of mood disturbances (Freeman et al., 2004; Harlow et al., 2003) . Change in serotonergic function, particularly serotonin 1A (5-HT 1A ) receptor function (Lemonde et al., 2003; Savitz et al., 2009; Shively and Bethea, 2004) , is a hallmark of such disorders (Halbreich, 1990; Jimerson et al., 1997; Joffe and Cohen, 1998; Ressler and Nemeroff, 2000) .
Selective serotonin reuptake inhibitors (SSRIs) are commonly used to treat mood disorders. Desensitization (attenuation) of both somatodendritic 5-HT 1A autoreceptor signaling in the midbrain dorsal raphe nucleus (DRN) and postsynaptic 5-HT 1A receptor signaling in the paraventricular nucleus (PVN) region of the hypothalamus are thought to contribute to the therapeutic efficacy of SSRIs (Lesch et al 1991 , Sargent et al 1997 , Bosker et al., 2001 Chaput et al., 1986; Czachura and Rasmussen, 2000; Lerer et al., 1999; Li et al., 1997; Gunther et al., 2008; Raap et al., 1999; Bleir and de Montigny, 1994) , which can take three to 12 weeks to achieve (Rush et al., 2004) . Multiple studies have provided direct evidence of a hyperactive hypothalamic-adreno-pituitary (HPA) axis response to the 5-HT 1A partial agonist buspirone, as evidenced by elevated adrenocorticotropic hormone (ACTH) and cortisol levels, which can be prevented by SSRI treatment (Navines et al., 2007; Gomez-Gil et al., 2010; Nikisch et al., 2005) . Desensitization of 5-HT 1A receptor signaling in the PVN can be measured by neuroendocrine challenge tests that detect changes in oxytocin (OT) and ACTH levels in response to 5-HT 1A receptor agonists (Li et al., 1997; Osei-Owusu et al., 2005) . In humans, chronic treatment with SSRIs reduces the release of OT and ACTH in response to 5-HT 1A receptor stimulation, thus demonstrating desensitization of the receptor signaling (Lerer et al., 1999) . These studies suggest that functional adaptative changes in postsynaptic 5-HT 1A receptor signaling underlie the effects of SSRIs.
Estrogens have been shown to enhance the efficacy of SSRIs for the treatment of mood disorders and hot flushes in women (Lomax and Schonbaum, 1993; Schneider et al., 1997) . In rats, SSRIs produce full desensitization of 5-HT 1A receptor signaling in the PVN in seven to 14 days (Li et al., 1996; Raap et al., 1999) , while estradiol alone can produce a partial desensitization with two days of treatment . Therefore, it is hypothesized that estrogen treatment in combination with SSRIs may accelerate SSRI therapeutic effects.
In order to improve current therapies for mood disorders, it is important to understand which estrogen receptor is involved in the regulation of 5-HT 1A receptors in the PVN. Of the two classical nuclear estrogen receptors (ERs) α and β, density of ERβ is higher than ERα in the PVN, especially in OT neurons (Alves et al., 1998; Hrabovszky et al., 2004; Laflamme et al., 1998; Simonian and Herbison, 1997) . Recent work in our laboratory has shown that ERβ is not involved in 5-HT 1A receptor desensitization (Rossi et al., 2010) . This result, together with the low expression of ERα in the PVN, led us to investigate the non-classical, membrane estrogen receptor GPR30. GPR30 binds estrogen with high affinity (Revankar et al., 2005; Thomas et al., 2005) , is expressed in the PVN, and colocalizes with 5-HT 1A receptors, OT, and corticotrophin releasing factor (CRF) in the PVN (Brailoiu et al., 2007; Sakamoto et al., 2007; Xu et al., 2009) . Previous work in our laboratory showed that treatment with the GPR30-selective agonist G-1 decreased 5-HT 1A receptor signaling, similar to estradiol (Xu et al., 2009) . These data suggest a role for GPR30 in the estradiolmediated desensitization of 5-HT 1A receptor signaling in the PVN.
The 5-HT 1A receptor is known to couple to the pertussis-toxin-insensitive G protein subunit Gαz (Barr et al., 1997; Raymond et al., 1993) . Stimulation of 5-HT 1A receptors in the hypothalamus stimulates release of OT and ACTH via coupling to Gαz (Serres et al., 2000) . Regulator of G protein signaling z1 (RGSz1), one of six splice variants of RGS20, is a highly selective GTP-activating protein (GAP) for Gαz. RGSz1 is exclusively found in the brain, where it accelerates hydrolysis of Gαz-bound GTP over 400-fold, with a K m of 2nM (Glick et al., 1998; Wang et al., 1998; Wang et al., 2002) . Two day treatment with estradiol produces a dose-dependent upregulation of RGSz1 in the PVN, without changing Gαz levels, that parallels the decreased hormone response induced by estradiol , suggesting that RGSz1 is important in estradiol-induced desensitization of 5-HT 1A signaling.
In this study, we investigated the hypothesis that GPR30 expression in the PVN is necessary for the estradiol-induced desensitization of 5-HT 1A receptor signaling. To test this hypothesis, we injected a recombinant adenovirus containing a small interference RNA (siRNA) against GPR30 into the rat PVN and then evaluated the effects of estradiol on 5-HT 1A receptor signaling, as well as changes in mRNA and proteins involved in 5-HT 1A receptor signaling, including the 5-HT 1A receptor, Gαz, and RGSz1.
Methods

Animals
Female Sprague-Dawley (SD) rats (225-250g) from Harlan (Haslett, MI) were housed two per cage in a temperature-, humidity-, and light-controlled room (12h light/dark cycle). Food and water were available ad libitum. All procedures were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and as approved by the University of Kansas Institutional Animal Care and Use Committee. All efforts were made to minimize animal discomfort and to reduce the number of animals used.
Drugs
17β-Estradiol-3-benzoate (EB) was purchased from Sigma-Aldrich (St. Louis, MO). EB was first dissolved in 100% ethanol to a concentration of 1mg/ml and then diluted with sesame oil to a concentration of 25 μg/ml. The EB solution and sesame oil were administered at 0.4 ml/kg (EB dose 10 μg/kg, subcutaneous (s.c.)). (+)8-Hydroxy-2-dipropylaminotetralin ((+)8-OH-DPAT) was purchased from Tocris (Ellisville, MO). (+)8-OH-DPAT was dissolved in 0.85% NaCl (saline) at a concentration of 0.2mg/ml and administered at a dose of 0.2mg/kg, s.c. Solutions were made fresh before injection.
Procedures
Experiment 1: effect of estradiol on 5-HT 1A receptor function-Prior to surgery, rats were anesthetized by an intraperitoneal (i.p.) injection of a cocktail of ketamine hydrochloride (100mg/kg) plus xylazine hydrochloride (7mg/kg). Rats were ovariectomized (OVX) by removing both ovaries via a single ventral midline incision. Five days after OVX, rats were given s.c. injections of either EB (10 μg/kg, 0.25ml/kg, s.c.) or vehicle (sesame oil) once a day for two days. In all experiments, plasma estradiol levels were reduced to below 10pg/ml by the seventh day after OVX, and two-day treatment with 10 μg/kg EB raised plasma estradiol levels to 100-140pg/ml. 18h following the last injection of EB or vehicle, rats were injected with the selective 5-HT 1A receptor agonist, (+)8-OH-DPAT (0.2mg/kg, s.c.) or vehicle (saline). 15 minutes later, animals were sacrificed by decapitation. Trunk blood was collected in centrifuge tubes containing 0.5ml 0.3M EDTA (pH 7.4). Brains were removed and snap-frozen in dry-ice-cooled isopentane and then placed in dry ice. Plasma and brains were stored at −80°C until use.
A full sequence of GPR30 (Accession No: U92802) was cloned into the target gene cloning site (SOS-GPR30-HUS). The siRNA or mismatch sequences were inserted into sfiI sites of SOS-GPR30-HUS (SOS-GPR30-siRNA-HUSs and SOS-GPR30-mis-HUSs, respectively) as described by Luo et al (2007) , followed by NotI digestion after ligation. The clones containing siRNA sequences were identified by PCR with U6 forward and siRNA antisense primers. The SOS-GPR30-siRNA-HUSs or SOS-GPR30-mis-HUSs were transfected into HEK293 cells using lipofectamine reagent (Invitrogen, Carlsbad, CA) to evaluate the knockdown efficiency of the GPR30 siRNAs. The number and density of GFP-expressing cells were observed for five consecutive days after the transfection.
The sequences of siRNAs in the SOS-GPR30-siRNA-HUS that significantly reduced the number and brightness of GFP-containing cells as well as SOS-GPR30-mis-HUSs that had no effect on GFP were selected and inserted into pSES-HUS vector, which is a shuttle vector for adenovirus and contains a red fluorescent protein (RFP), as described above and Luo et al (2007) . The SES-GPR30-siRNA-HUSs and SES-GPR30-mis-HUSs were further recombined into Ad-Easy-1 vector to generate high titer adenoviruses containing the GPR30 siRNA or mismatch sequences (GPR30-siRNA-Ads and GPR30-mis-Ads, respectively) (He et al., 1998) . The high titer GPR30-siRNA-Ads and GPR30-mis-Ads (~10 11-12 active viral particles/ml) were stored at −80°C. Before use, the high titer adenoviruses were dialyzed with saline for at least 40min at 4°C followed by 1:1 dilution with saline to reduce tissue damage caused by the high-salt storage solution.
To test the GPR30-siRNA-Ads in vivo, we conducted two studies. First, we tested the timecourse of GPR30 knockdown by GPR30-siRNA-Ads. Then, we confirmed that knockdown of GPR30 was due to the GPR30-siRNA-Ads and not due to the viral injection or infection. Rats were anesthetized and OVX as described in experiment 1, then given unilateral intra-PVN injections of GPR30-siRNA-Ads (402, 737, and 1135 combined) using stereotaxic technique at a rate of 0.5 μl/min, 1 or 2 μl/side at the coordinates of AP= −1.8, ML= 0.5 and DV= −8.3 mm with respect to the bregma. The needle (31 gage) was left in the injection site for an additional 20min to reduce movement of the viral solution into the needle track. Three, five, or 10 days after injection, rats were sacrificed and the brains were removed. Brains were sectioned into 300 μm sections using a cryostat. Regions with viral injection as indicated by RFP and the contralateral regions (as controls) were punched out for immunoblot analysis of GPR30. The percent inhibition of GPR30-siRNA-Ads was calculated by comparing the ratio of GPR30:β-actin between the injected side (I) and the contralateral side (C) of each animal (% inhibition = (1−I/C) × 100%).
To confirm that observed knockdown of GPR30 protein was due to the GPR30-siRNA-Ads and not a result of the virus itself or tissue damage caused by the injection, OVX rats were given unilateral intra-PVN injections of saline, control-Ad (Adtrack, empty recombinant shuttle vector), GPR30-mis-Ads (737 and 1135 combined), or GPR30-siRNA-Ads (402, 737, and 1135 combined) using stereotaxic technique as described above. Five days after injection, rats were sacrificed and the brains were collected to evaluate the efficiency of knockdown of GPR30 expression by the siRNAs, compared to the various controls, as described above.
Effect of GPR30-siRNA-Ad on EB-induced desensitization of 5-HT 1A receptors in the PVN: Rats were anesthetized and OVX as described above, then given bilateral intra-PVN injections of control-Ad or GPR30-siRNA-Ads (402, 737, 1135 combined) using stereotaxic technique at a rate of 0.5 μl/min, 1 μl/side at the coordinates of AP= −1.8, ML= ±0.5, and DV= −8.3 mm with respect to bregma. The needle was left in the injection site for an additional 20min to reduce movement of the viral solution into the needle track. Five days after OVX and viral injection, rats were treated with either 10 μg/kg/day EB or oil (s.c.) once a day for two days. 18h after the last EB or oil treatment, rats were injected with 0.2mg/kg (+)8-OH-DPAT or saline (s.c.) and sacrificed via decapitation 15 minutes later. Brains were removed and snap-frozen in dry-ice-cooled isopentane and then placed in dry ice. Trunk blood was collected in tubes containing 0.5ml 3M EDTA (pH 7.4). Brains and plasma were stored at −80°C until use.
Radioimmunoassay of plasma OT and ACTH: Plasma OT was determined by a radioimmunoassay as previously described with minor modifications (Li et al., 1997) . Briefly, OT was extracted from 0.5 ml plasma with 1ml cold acetone followed by 2.5ml petroleum ether. The ether layer was aspirated and the samples were dried in a Centrivap vacuum concentrator at 4°C. The dried OT residue was resuspended in 1ml of cold assay buffer (0.05M phosphate buffer pH 7.4 containing 0.125% bovine serum albumin and 0.001M EDTA). The plasma extracts were used for the radioimmunoassay as previously described. The radioactive 125 I oxytocin (specific activity: 2200 Ci/mmol) was obtained from Perkin Elmer (Waltham, MA). Several standard recovery samples containing 0.5ml pooled plasma and 8 and 16 pg OT were included throughout the extraction and assay procedure. The plasma OT concentrations were calculated based on the recovery and dilution factors. Plasma ACTH concentrations were determined by radioimmunoassay as previously described (Li et al., 1993) . 125 I ACTH (0.00102mCi) was obtained from DiaSorin (Stillwater, MN).
Quantitative Real-Time PCR: RNA was isolated from the PVN using TRI-Reagent according to the manufacturer's instruction (Sigma-Aldrich, St. Louis, MO). Briefly, 5 μg RNA was treated with 5 μl DNase I in DNase I buffer (total reaction volume 50 μl) for 15min at room temperature; the reaction was stopped with 5 μl 25mM EDTA followed by incubation at 65°C for 10min. 10 μl of the DNase-treated RNA reaction mixture was incubated with 1 μl 0.3M oligo(dT) 20 and 1 μl 10mM dNTPs at 65°C for 5 minutes. A master mix containing 5x reverse transcriptase buffer, 0.1M DTT, RNase Out, and 200 units Superscript II enzyme (Invitrogen, Carlsbad, CA) was added to each sample according to the manufacturer's protocol. The reverse transcription was performed by incubation at 42°C for 50min and then reaction was stopped by incubation at 70°C for 15min. To cleave RNA templates, 1 μl RNase H was then added to the reaction which was then incubated at 37°C for 20 min. The complimentary DNA (cDNA) generated was used for real-time PCR.
Real-time quantitative PCR (qPCR) was performed in 96-well plates using SYBR Green Plus master mix (Invitrogen, Carlsbad, CA) and the Applied Biosystems 7500 Fast RealTime PCR system (Applied Biosystems, Carlsbad, CA). mRNA levels of GPR30 (forward primer: CCACGCTCAAGGCAGTCATA; reverse primer: GCACTGCTGAACTTGACATCTGA), 5-HT 1A receptor (forward primer: GATCTCGCTCACTTGGCTCAT; reverse primer: GCGCCAGCCCAGCAT), and RGSz1 (forward primer: AGACATTCCAGCGTGTGAAGAA; reverse primer: GGGCCCAGGCACAGACTT) were examined. The mRNA levels were normalized to TATA-box binding protein (TBP) mRNA (forward primer: CAGGAGCCAAGAGTGAAGAACA; reverse primer: GCTTCTGCACAACTCTAGCGTATT). Each qPCR reaction was conducted in a total volume of 20 μl, containing 2 μl cDNA, 0.2 μM of each primer, and 10 μl SYBR Green Plus master mix. PCR was performed at 50°C for 2min, 95°C for 10min, then 40 cycles of 95°C for 15s and 60°C for 1min per cycle. All samples were run in triplicate. ΔCt was calculated as the target gene -TBP mRNA for each sample; ΔΔCt was calculated as ΔCt for the experimental condition − ΔCt for the control condition, for each target gene.
Immunoblot assays:
The PVN was punched out from 300 μm-thick sections prepared using a cryostat microtome. PVN tissue was homogenized in 100 μl homogenization buffer (10mM Tris pH 7.6, 100mM NaCl, 1mM EDTA, 1% sodium cholate, 1% phosphatase inhibitor cocktail (Sigma-Aldrich, St. Louis, MO), 0.1% protease inhibitor cocktail (SigmaAldrich, St. Louis, MO)) by brief sonication followed by shaking for 1hr at 4°C. Samples were then centrifuged at 25,000×g for 1hr; the supernatant was collected and stored at −80°C. Protein concentration was measured using the Pierce BCA protein assay (Thermo Scientific, Rockford, IL). Protein (10 μg/lane) was resolved on a 12% SDS-PAGE gel followed by transfer to polyvinylidene fluoride (PVDF) membrane. The membranes were incubated in blocking buffer (5% milk in Tris-buffered saline with 0.1% Tween-20) to reduce non-specific binding and probed overnight using the following primary antibodies: rabbit anti-GPR30 (1:1000, Novus Biologicals, Littleton, CO); rabbit anti-5-HT 1A receptor (1:1000, Abcam Cat.#85615, San Francisco, CA); rabbit anti-Gαz (1:2000, Santa Cruz Biotechnology, Santa Cruz, CA); rabbit anti-RGSz1 (1:5000); rabbit anti-ERβ (1:1000, Alexis Biochemicals/Enzo Life Sciences, Plymouth Meeting, PA). After washing, membranes were incubated with the appropriate secondary antibody conjugated with horse radish peroxidase. Bands were detected with ECL substrate solution (GE Healthcare Biosciences, Piscataway, NJ) using BioRad ChemiDoc XRS+ molecular imager (BioRad, Hercules, CA). Due to the limited amount of PVN protein, all primary antibodies were used on the same blots, with washing in between uses. Monoclonal mouse actin antibody (1:10 000, MP Biomedicals, Solon, OH) was used as a loading control. Bands were analyzed densitometrically (integrated optical density, IOD) using ImageLab software (BioRad, Hercules, CA). Each band was normalized to actin and calculated as percent of the control group in each blot. All samples were run in duplicate or triplicate.
Characterization of anti-RGSz1: RGSz1 antiserum was raised in rabbits against the last 15 amino acids of the C-terminal of RGSz1 (YKDLLTSLAEKTVEA) and affinity purified by Biosynthesis (Lewisville, TX). To characterize the antibody, the full sequence of RGSz1 was inserted into a pcDNA vector (Invitrogen, Carlsbad, CA) which was then transfected into HEK293 cells. Cell lysates were collected, protein was resolved by SDS-PAGE, and Western blotting was performed as described above. Representative Western blot is shown in Figure 2A (left).
Microscopy: 18 μm-Thick tissue sections were collected from the beginning, middle, and end of each 300 μl PVN section as described above to evaluate RFP expression. Images were captured using a Nikon Eclipse Ti2000 and Metamorph Software (Molecular Devices, Sunnyvale, CA) at 4x magnification.
Statistical analysis: All data are expressed as means ± SEM. Two-or three-way analysis of variance (ANOVA) and Student-Newman-Keuls post hoc tests were conducted using a statistical program (Statview version 5.0 software, SAS Institute Inc., Cary, NC).
Results
Experiment 1: Effects of EB on 5-HT 1A receptor signaling in the PVN EB induces desensitization of 5-HT 1A receptor signaling: In our first experiment, female SD rats were OVX and treated with EB (10 μg/kg/day) for two days. To confirm that twoday EB treatment resulted in desensitization of 5-HT 1A receptor signaling in our rat model, 18 hours after the second EB injection, the rats were challenged with the selective 5-HT 1A receptor agonist (+)8-OH-DPAT (0.2mg/kg) and plasma hormone levels were examined. EB treatment did not alter the baseline levels of plasma OT in comparison to vehicle treatment ( Figure 1A) . Activation of 5-HT 1A receptors by (+)8-OH-DPAT increased plasma OT levels in oil-treated rats as expected. The magnitude of the OT response to (+)8-OH-DPAT was significantly reduced in EB-treated rats (two-way ANOVA: main effect of (+)8-OH-DPAT: F (1,25) =299, p<0.0001; main effect of EB: F (1,25) =11.2, p<0.01; interaction between EB and (+)8-OH-DPAT: F (1,25) =12.2, p<0.01).
Baseline levels of plasma ACTH were unchanged by two-day EB treatment (Figure 1B) , and stimulation of 5-HT 1A receptors by (+)8-OH-DPAT increased plasma ACTH levels significantly. The ACTH response to (+)8-OH-DPAT was significantly reduced in EBtreated animals compared to oil treatment (two-way ANOVA: main effect of (+)8-OH-DPAT: F (1,27) =533, p<0.0001; main effect of EB: (F (1,27) =9.47, p<0.01; interaction between EB and (+)8-OH-DPAT: F (1,27) =11.0, p<0.01). Thus, both oxytocin and ACTH plasma concentration results suggest the desensitization of 5-HT 1A receptor signaling in the PVN.
EB treatment alters expression of components of the 5-HT 1A receptor signaling pathway To determine the cellular mechanisms mediating desensitization of 5-HT 1A receptor signaling, we examined effects of EB treatment on the 5-HT 1A receptor system in the PVN at the molecular level. EB reduced the protein levels of 5-HT 1A receptors by 32% as measured on Western blots (Figure 2A , right) (F (1,5) =9.08, p<0.05). Two RGSz1 bands (55kD, 45kD) were measured. The protein levels in both bands were significantly increased by 79% (F (1,5) =21.8, p<0.01) and 25% (F (1,5) =6.75, p<0.05), respectively, in the EB group compared to the oil-treated group. There were no significant differences in the protein levels of either Gαz protein (F (1,5) =2.26, p=0.21) or GPR30 protein (F (1,5) =0.32, p=0.59) ( Figure 2B ).
Quantitative real-time PCR was conducted to further examine the expression of components of the 5HT 1A receptor signaling pathway. Our results showed that EB treatment increased mRNA levels of 5-HT 1A receptor by 299% (EB vs. oil, F (1,6) =6.13, p<0.05). RGSz1 mRNA levels increased by 308% (EB vs. oil, F (1,6) =10.2, p<0.05), while GPR30 mRNA did not change significantly (F (1,6) =0.0001, p=0.99) ( Figure 2C ).
Experiment 2: effects of reduction in the GPR30 expression on EB-induced desensitization of 5-HT 1A receptor in the PVN
Generation and evaluation of GPR30-siRNA-Ads: To select efficient GPR30 siRNA sequences, SOS-GPR30-siRNA-HUSs and SOS-GPR30-mis-HUSs were transfected into HEK293 cells. The cells transfected with GPR30-siRNA-HUS 402, 737 and 1135, but not 272 (numbers refer to first base pairs of each siRNA sequence), displayed reductions in the number of GFP-containing cells and the intensity of GFP compared to SOS-GPR30-mis-HUS and SOS-GPR30-HUS plasmids, beginning two days after transfection. Therefore, we selected the 402, 737, and 1135 siRNA constructs for production of GPR30 siRNA recombinant adenovirus (GPR30-siRNA-Ad). Figure 3A shows examples from 3 days after transfection.
To test the time course of GPR30 knockdown by GPR30-siRNA-Ads, we unilaterally injected 1 or 2 μl GPR30-siRNA-Ads into the PVN of rats ( Figure 3B ) and collected the brains 3, 5 and 10 days after the injection. By comparing GPR30 expression in the viral infected sides to their contralateral sides, we observed that the GPR30-siRNA-Ads significantly inhibited the expression of GPR30 in a dose-dependent manner (% inhibition: 59 ± 8 (n=3) for 1 μl vs. 78± 5 (n=6) for 2 μl viral injection). This inhibition of GPR30 expression was observed 3 days after the injections. There was no difference in inhibition between 3 and 5 days, but there was a slight, non-significant reduction in inhibition 10 days after the injection (89% inhibition for 3 days, 86% for 5 days and 66% for 10 days after 2 μl viral injection). These data demonstrated that the GPR30-siRNA-Ads are able to efficiently knock down GPR30 expression 3 days after injection. Although no visible tissue damage was observed, to avoid possible toxicity and to restrict the knockdown of GPR30 to the PVN, we used 1 μl of GPR30-siRNA-Ads and the 5 day time point in further studies.
To compare the effects of the GPR30-siRNA-Ads with the GPR30-mis-Ads in vivo, we unilaterally injected 1 μl of GPR30-siRNA-Ads into the PVN, with saline, empty viral vector (Adtrack, control-Ad), or GPR30-mis-Ads as controls. In the GPR30-siRNA-Ads construct, red fluorescent protein (RFP) is expressed independently of the siRNAs, making the presence of RFP useful for tracking the virus infection ( Figure 3C ). Five days after the injection of the virus, GPR30 protein level in the viral-infected side was measured and percent inhibition was calculated relative to the contralateral (non-injected) side of each animal (representative Western blots shown in Figure 3D ). The GPR30-siRNA-Ads were successful in reducing GPR30 protein expression by about 42%, compared to the contralateral side (F (3,10) =6.23, p<0.01). None of the three controls had a significant effect on GPR30 protein levels ( Figure 3E ). However, in a separate experiment (not shown), GPR30-mis-Ads interfered with the neuroendocrine response. Therefore, we used controlAd as the control for the following experiment.
Effect of GPR30-siRNA-Ads on GPR30 in the PVN:
To determine the role of GPR30 in the EB-induced desensitization of 5-HT 1A receptor signaling in the PVN, we performed bilateral injections of control-Ad or GPR30-siRNA-Ad constructs in the PVN of OVX rats. Five days after viral injection, rats were treated with 10 μg/kg/day EB or oil (s.c.) for two days and then challenged with 0.2mg/kg (+)8-OH-DPAT (s.c.) before being sacrificed, as described above. Knockdown of GPR30 was verified by Western blotting ( Figure 4A ). We used both reduction in GPR30 levels and the location of RFP expression as exclusion criteria for incorrect injections of GPR30-siRNA-Ads; rats with no RFP or RFP that was not in the PVN were excluded from subsequent analyses. GPR30 protein was successfully reduced to about 68% of control (F (1,12) =7.89, p<0.05) ( Figure 4B ). This 32% inhibition is a little lower than the reduction in the previous test. This could be due to the way tissue was collected and GPR30 levels compared: we measured GPR30 in the entire PVN if there was viral infection in at least part of the PVN, whereas previously we only injected one side of the PVN and only used tissue that had RFP expression. ERβ expression can be influenced by treatment with estradiol (Rossi et al., 2010) ; to ensure that effects of EB on 5-HT 1A receptor signaling in the neuroendocrine challenge tests were due to the reduction of GPR30 and not a change in ERβ levels, we measured ERβ protein in the PVN following infection with GPR30-siRNA-Ads and found no significant change (F (1,15) =1.91, p=0.18) ( Figure   4B ).
Effect of GPR30-siRNA-Ads on EB-induced desensitization of 5-HT 1A receptor signaling: Desensitization of 5-HT 1A receptor signaling was examined by measuring the plasma levels of OT ( Figure 5A ) and ACTH ( Figure 5B ). The baseline level of plasma OT was not altered by EB treatment or GPR30-siRNA-injection. In animals injected with the control-Ad, activation of 5-HT 1A receptors by (+)8-OH-DPAT increased plasma OT levels. In the control-Ad-infected group, there was a significant reduction in OT response to (+)8-OH-DPAT after EB treatment compared to oil treatment, demonstrating desensitization of 5-HT 1A receptor signaling. In the GPR30-siRNA-Ads-injected group, OT levels in response to (+)8-OH-DPAT were not significantly different from the control-Ad-injected, oil-treated group, and EB treatment did not induce 5-HT 1A receptor signaling desensitization (threeway ANOVA: main effect of viral injection, F (1,56) =2.19, p=0.14; main effect of (+)8-OH-DPAT, F (1,56) =1219, p<0.0001; main effect of EB, F (1,56) =4.21, p<0.05; interaction between EB and (+)8-OH-DPAT, F (1, 56) =2.16, p=0.15 ; interaction between EB and viral injection, F (1,56) =0.72, p<0.5; interaction between (+)8-OH-DPAT and viral injection, F (1,56) =2.39, p=0.13; interaction between EB, (+)8-OH-DPAT, F (1,56) =0.39, p=0.76).
Plasma ACTH levels in response to (+)8-OH-DPAT showed a similar pattern. Neither EB treatment nor GPR30-siRNA-Ad injection had an effect on baseline levels of plasma ACTH. In animals injected with the control-Ad, activation of 5-HT 1A receptors by (+)8-OH-DPAT increased plasma ACTH levels, while EB treatment produced a significant reduction in ACTH response to (+)8-OH-DPAT, demonstrating desensitization of 5-HT 1A receptor signaling. In the GPR30-siRNA-Ad-injected group, ACTH levels in response to (+)8-OH-DPAT were not significantly different from the control-Ad-injected, oil-treated group, and EB treatment did not have an effect on plasma ACTH levels (three-way ANOVA: main effect of viral injection, F (1,62) =1.94, p=0.17; main effect of (+)8-OH-DPAT, F (1,62) =802, p<0.0001; main effect of EB, F (1,62) =0.69, p=0.41; interaction between (+)8-OH-DPAT and EB, F (1, 62) =1.93, p=0.17 ; interaction between (+)8-OH-DPAT and viral injection, F (1, 62) =0.38, p=0.77; interaction between EB and viral injection, F (1, 62) =5.12, p=0.27 ; interaction between (+)8-OH-DPAT, EB, and viral injection, F (1,62) =5.04, p<0.05).
To further investigate the effects of EB treatment on 5-HT 1A receptor signaling, we next examined 5-HT 1A receptor protein and the G protein mediating the hormone responses, Gαz, using Western blotting ( Figure 6A ). EB pretreatment resulted in reduced levels of 5-HT 1A receptor protein in the control-Ad-injected group (F (1,35) =6.69, p<0.001); this effect was not seen in the GPR30-siRNA-Ad-injected group, further suggesting that GPR30 may be involved in the reduction of 5-HT 1A receptor protein. The GPR30-siRNA-Ad injection itself had no effect on 5-HT 1A receptor protein levels. Levels of Gαz protein were unchanged, regardless of treatment (F (1,35) =1.05, p=0.39) ( Figure 6B ).
Discussion
We previously reported that 2-day peripheral administration of EB resulted in the desensitization of 5-HT 1A receptor signaling in the rat PVN . Our previous study demonstrated that this desensitization is not mediated by ERβ, as treatment with a selective ERβ agonist, DPN, did not mimic the results of EB treatment.
Furthermore, siRNA knockdown of ERβ in the PVN did not prevent EB-induced desensitization of 5-HT 1A receptor signaling (Rossi et al., 2010) . However, 2-day intra-PVN injections of the selective GPR30 agonist, G-1, did result in desensitization of 5-HT 1A receptor signaling (Xu et al., 2009) . Therefore, in this study we chose to focus on the role of GPR30. We show for the first time that GPR30 expression is necessary for the EB-induced desensitization of 5-HT 1A receptor signaling, and that this mechanism involves a decrease in 5-HT 1A receptor protein expression and possibly an increase in the rate of Gαz-GTP hydrolysis, as suggested by an increase in RGSz1 protein expression.
To identify the role of GPR30 in EB-induced changes in 5-HT 1A receptor signaling, we injected an adenovirus containing siRNA sequences against GPR30 directly into the PVN. Treatment with GPR30-siRNA-Ads produced a modest reduction of GPR30 protein, by about 32%. Despite such a modest reduction in GPR30 protein, GPR30-siRNA-Ads infection was successful in completely preventing the reduction of both the OT and ACTH hormone responses to (+)8-OH-DPAT produced by EB treatment, reinforcing the hypothesis that GPR30 is necessary for estradiol-induced 5-HT 1A receptor desensitization.
To further elucidate the GPR30-mediated mechanism through which EB impacts 5-HT 1A receptor desensitization, we examined changes in the 5-HT 1A receptor signaling pathway. Two-day treatment with EB resulted in a decrease in 5-HT 1A receptor protein in the PVN, which is consistent with previous studies that have reported a decrease in 5-HT 1A receptor binding sites in the hypothalamus and DRN of nonhuman primates (Lu and Bethea, 2002) and reduced 5-HT 1A receptor protein levels in the DRN (Henderson and Bethea, 2008) after chronic estradiol treatment. In contrast, we found that 2-day EB treatment increased 5-HT 1A receptor mRNA. This upregulation of 5-HT 1A receptor mRNA in the PVN may be a feedback response to the decrease in protein levels induced by estradiol, or estradiol signaling may be affecting 5-HT 1A receptor translational control. Other studies have demonstrated that acute estradiol administration decreased 5-HT 1A receptor gene expression in the rat limbic system (Osterlund and Hurd, 1998) , while chronic estradiol decreased 5-HT 1A receptor mRNA in the rat DRN (Birzniece et al., 2001 ) but increased 5-HT 1A receptor mRNA in the DRN in nonhuman primates (Pecins-Thompson and Bethea, 1999) . These discrepancies could be due to tissue-specific regulatory mechanisms, differences in chronic versus short-term estradiol administration, or species differences. Notably, the 32% reduction in GPR30 induced by infection with the GPR30-siRNA-Ads prevented the EBinduced changes in 5-HT 1A receptor protein, thus reinforcing an important role for GPR30 in this mechanism.
There are some studies linking changes in 5-HT 1A receptor expression to depression in human female patients (Szewczyk et al., 2009) , which would indicate a role for estradiol in mediating 5-HT 1A receptor expression as well as function. Pet-1, which is necessary for development of the serotonin system (Hendricks et al., 1999; Hendricks et al., 2003; Iyo et al., 2005; Maurer et al., 2004) , directly binds to Pet-1 elements in the human 5-HT 1A receptor promoter region, and is critical for 5-HT 1A receptor expression in the midbrain (Jacobsen et al., 2011) . In macaques, long-term OVX reduced expression of Pet-1 in the DRN (Bethea et al., 2011) , while in rats, two-day administration of estradiol after OVX increased Pet-1 mRNA levels in the DRN (Rivera et al., 2009) , indicating a clear role for regulation of midbrain 5-HT 1A receptor expression by estradiol. A reduction in inhibitory DRN 5-HT 1A autoreceptors, induced by estradiol via Pet-1, may play a role in desensitizing post-synaptic 5-HT 1A receptors in the PVN by increasing serotonergic tone, similar to chronic SSRI treatment.
Though GPR30 is a membrane receptor that signals through heterotrimeric G proteins, studies have demonstrated that signaling through GPR30 has effects on gene transcription independent of classical estrogen response elements (Albanito et al., 2007; Maggiolini et al., 2004) . GPR30 has been shown to act independently of ERα and ERβ to stimulate the MAPK/ERK1/2 signaling system via a Bordetella-pertussis-toxin-sensitive (PTX), Gβγ pathway (Filardo, 2002; Filardo et al., 2000) . We showed previously that treatment with PTX inhibits modulation of 5-HT 1A receptor signaling by estradiol (Xu et al., 2009) , which again suggests that GPR30 signaling plays a role in this mechanism. In the current study, we saw an estradiol-induced decrease in 5-HT 1A receptor expression that was precluded by GPR30 protein reduction. This suggests that estradiol could alter 5-HT 1A receptor expression levels through the GPR30-Gβγ, MAPK/ERK1/2 pathway by transiently decreasing 5-HT 1A receptor mRNA in the PVN. The subsequent decrease in 5-HT 1A receptor protein levels could then feedback to lead to upregulation of mRNA expression, though the mechanisms remain unclear 5-HT 1A receptors in the PVN are coupled to the G protein Gαz to stimulate OT and ACTH (via CRF) release (Barr et al., 1997; Raymond et al., 1993; Serres et al., 2000) . Previous studies have shown that chronic estradiol treatment results in decreased DRN protein levels of Gαi 3 , but not Gαi 1 , Gαi/o, or Gαz in nonhuman primates (Lu and Bethea, 2002) . Similarly, in the present study we found that 2-day EB administration had no effect on Gαz protein or mRNA levels in the PVN. These results are consistent with previous reports showing that estradiol treatment does not affect levels of Gαz protein in the rat PVN D'Souza et al., 2004) . Knockdown of GPR30 by GPR30-siRNA-Ads also had no effect on Gαz levels, indicating that GPR30 signaling does not regulate Gαz protein levels, and that alteration of Gαz levels is not responsible for estradiol-mediated 5-HT 1A receptor desensitization.
While a decrease in 5-HT 1A receptor protein expression may play a role in EB-induced desensitization, it is interesting that estradiol treatment also reduces 5-HT 1A receptor function Uphouse, 1996, 1998; Raap et al., 2000) and coupling to G proteins (Mize and Alper, 2000) , though we show that Gαz protein expression is not affected by EB. We therefore examined protein and mRNA expression of RGSz1, the GAP that is highly selective for Gαz (Glick et al., 1998; Wang et al., 1998; Wang et al., 2002) . Consistent with a previous report , we found that 2-day EB treatment increased RGSz1 protein and now have found an increase in RGSz1 mRNA in the PVN. By increasing the hydrolysis of Gαz-GTP by over 400-fold (Wang et al., 1998) , high levels of RGSz1 could effectively reduce the ability of Gαz to activate downstream effectors and hormone release upon 5-HT 1A receptor stimulation, thus contributing to the desensitized response. Work is currently being done in our laboratory to investigate the potential interactions between RGSz1, Gαz, and 5-HT 1A receptors.
Since OT-containing neurons express very little ERα (Simonian and Herbison, 1997), we have not yet directly addressed ERα as a potential candidate for desensitization of 5-HT 1A receptor signaling. However, some studies have shown that hypothalamic neurons, as well as other cell types, have a number of ERα splice variants that are located in the plasma membrane and could mediate estradiol signaling (Acconcia et al., 2005; Bollig and Miksicek, 2000; Dominguez et al., 2009; Dominguez and Micevych, 2010; Gorosito et al., 2008; Ishunina and Swaab, 2008; Li et al., 2003) . Recent studies have found a novel, membrane-targeted, 36kD splice variant (ERα36) with a unique C-terminal sequence in human tissues and human cell lines (Wang et al., 2005; Zou et al., 2009) , and suggest that ERα36 may be involved in responses heretofore believed to be mediated by GPR30. In ERnegative breast cancer cell lines that express ERα36 (e.g. MDA-MB-231 and SK-BR-3), the selective estrogen receptor modulator tamoxifen and ER antagonist ICI 182, 780 were unable to block nongenomic estrogen signaling (Lee et al., 2008; Wang et al., 2006) , similar to effects seen when GPR30 is expressed (Filardo et al., 2006) . A recent study by Kang et al. (2010) demonstrated that GPR30 expression and signaling induced ERα36 expression, that G-1 specifically binds and activates ERα36, and that ERα36 mediates nongenomic estrogen signaling independent of GPR30 in full-length-ERα-negative but ERα36-positive breast cancer cells. They suggest that GPR30 signals through the Src/MAPK/AP-1 pathway to activate ERα36 promoter activity and induce ERα36 expression, and that G-1 may be an agonist for ERα36, not GPR30. Other studies have reported ERα36 effects or immunoreactivity in rodent tissues; however, they failed to directly demonstrate expression of this splice variant (Jia et al., 2011; Patkar et al., 2011) . Indeed, we performed immunohistochemical staining of rat brain tissue using the antibody kindly provided by Wang's group (Wang et al., 2006) , raised against the unique C-terminal sequence of ERα36, and found strong immunoreactivity in neurons throughout the rat brain. However, we conducted a BLAST search for the unique 88 base pair sequence of human ERα36 in the rat genome and no comparable sequence was detected. These data suggest that while it is possible that the rat brain may contain an ERα splice variant that plays a role in estradiol-GPR30 signaling, this putative splice variant is not the same as the ERα36 described in humans.
The results of this study demonstrate that GPR30 expression is necessary for estradiolinduced desensitization of 5-HT 1A receptor signaling in the PVN, and that the mechanism likely involves a decrease in 5-HT 1A receptor protein levels and an increase in RGSz1 expression. Further studies are needed to clarify whether ERα or any of its splice variants play a role in this mechanism. Because the effects of SSRIs occur slowly and are thought to involve desensitization of pre-synaptic and post-synaptic 5-HT 1A receptors (Bosker et al., 2001; Chaput et al., 1986; Czachura and Rasmussen, 2000; Rush et al., 2004; Li et al., 1997; Gunther et al., 2008; Raap et al., 1999, Bleir and de Montigny, 1994) , elucidating the estrogen-receptor-mediated mechanisms that result in rapid desensitization of 5-HT 1A signaling will be important in the design of novel treatments that activate specific estrogen receptors in conjunction with SSRI therapy, for the improved treatment of depression and other mood disorders. EB-induced changes in 5-HT 1A signaling pathway. A) Left, characterization of RGSz1 antibody. RGSz1 protein at approximately 27kD was detected in HEK293 cells transfected with a vector expressing RGSz1 protein but not empty-vector transfected cells. In rat PVN, higher molecular weight proteins were also detected most likely due to post-translational modifications. Lane 1, HEK293 cells transfected with RGSz1. Lane 2, HEK293 cells transfected with empty vector (pcDNA). Lane 3, PVN tissue lysate. Right, Western blot of PVN protein after oil or EB treatment with antibodies against GPR30, 5-HT 1A , Gαz, and RGSz1, with β-actin as a loading control. B) Quantitation of protein levels after EB pretreatment. Bands were analyzed densitometrically (integrated optical density, IOD). Each band was normalized to β-actin and expressed as percent of control (oil). Data are expressed as mean ± SEM (n=6), *p<0.05, **p<0.001 by Student-Newman-Keuls post hoc test. C) Generation and evaluation of recombinant adenoviruses containing GPR30-siRNAs. A) Selection of GPR30-siRNAs: SOS-GPR30-siRNA-HUS (left panels), SOS-GPR30-missiRNA-HUS (right panels), and SOS-GPR30-HUS (control) (right panels) constructs were transfected into HEK293 cells. The number and brightness of GFP-containing cells were observed three days after the transfection. B) Diagram of PVN injection site. F = fornix. Vertical line represents the 3rd ventricle. PVN is within the dashed triangle. C) An example of RFP expression in the PVN five days after unilateral injection of GPR30-siRNA-Ads. 3V = 3rd ventricle. D) Examples of Western blot for GPR30 protein from PVN tissue with unilateral injection of saline, control-Ad, GPR30-mis-Ads, and GPR30-siRNA-Ads five days after infection. E) Quantitation of GPR30 knockdown. Bands were measured densitometrically and normalized to β-actin. The percent inhibition of GPR30-siRNA-Ads was calculated by comparing the ratio of GPR30:β-actin between the injected side (I) and the contralateral side (C) of each animal (% inhibition = (1−I/C) × 100%). Data are presented as mean percent inhibition. ± SEM (n=4-5). *p<0.05 by Student-Newman-Keuls post hoc test. Confirmation of GPR30 knockdown. A) Examples of Western blots of GPR30 and ERβ with β-actin as loading control in GPR30-siRNA-Ad-and control-Ad-injected PVN. B) Quantitation of GPR30 knockdown and ERβ protein levels in the PVN of GPR30-siRNAAd-and control-Ad-injected rats. Bands were measured densitometrically and normalized to β-actin. Data are expressed as mean percent of control-Ad ± SEM (n=4-7), *p<0.01 by Student-Newman-Keuls post hoc test. Effects of GPR30-siRNA-Ads on plasma OT (A) and ACTH (B) responses to (+)8-OH-DPAT in EB-treated rats. Data are expressed as mean ± SEM, (n=7-10). *Indicates significantly different from saline-challenged animals with same treatment, p<0.0001, #indicates significantly different from control-Ad/oil-treated rats with same challenge, p<0.05 by Student-Newman-Keuls post hoc test. GPR30-siRNA-Ads prevented EB-induced reductions of 5-HT 1A receptor protein in the PVN. A) Representative Western blots of 5-HT 1A receptor and Gαz protein levels with β-actin loading control in the PVN of rats injected with control-Ad or GPR30-siRNA-Ad followed by treatment with oil or EB. B) Quantitation of Western blots. Bands were measured densitometrically and normalized to β-actin. Data are expressed as mean percent of control-Ad/oil, ± SEM (n=7-12). *p<0.001 by Student-Newman-Keuls post hoc test.
